China's National Healthcare Security Administration has released preliminary information regarding the 2026 basic medical insurance catalog and commercial insurance innovation drug catalog adjustments. The review process saw an increase in submitted applications, with 818 materials received for 674 generic names, up from the previous year. Notably, the preliminary review pass rate was high at 92%, and the majority of submitted drugs were new, with 343 applications citing the condition of being a new generic drug approved within the last five years. AI
RANK_REASON Regulatory action by a major government body concerning drug approvals and insurance catalogs. [lever_c_demoted from significant: ic=1 ai=0.4]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
